Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Breast Cancer Research
  • View item
  • Home
  • ICR Divisions
  • Breast Cancer Research
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Cells Lacking the <i>RB1</i> Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival.

Thumbnail
View/Open
Accepted version (6.294Mb)
Date
2019-02
ICR Author
Lord, Christopher
Author
Oser, MG
Fonseca, R
Chakraborty, AA
Brough, R
Spektor, A
Jennings, RB
Flaifel, A
Novak, JS
Gulati, A
Buss, E
Younger, ST
McBrayer, SK
Cowley, GS
Bonal, DM
Nguyen, Q-D
Brulle-Soumare, L
Taylor, P
Cairo, S
Ryan, CJ
Pease, EJ
Maratea, K
Travers, J
Root, DE
Signoretti, S
Pellman, D
Ashton, S
Lord, CJ
Barry, ST
Kaelin, WG
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Small cell lung cancer (SCLC) accounts for 15% of lung cancers and is almost always linked to inactivating RB1 and TP53 mutations. SCLC frequently responds, albeit briefly, to chemotherapy. The canonical function of the RB1 gene product RB1 is to repress the E2F transcription factor family. RB1 also plays both E2F-dependent and E2F-independent mitotic roles. We performed a synthetic lethal CRISPR/Cas9 screen in an RB1 -/- SCLC cell line that conditionally expresses RB1 to identify dependencies that are caused by RB1 loss and discovered that RB1 -/- SCLC cell lines are hyperdependent on multiple proteins linked to chromosomal segregation, including Aurora B kinase. Moreover, we show that an Aurora B kinase inhibitor is efficacious in multiple preclinical SCLC models at concentrations that are well tolerated in mice. These results suggest that RB1 loss is a predictive biomarker for sensitivity to Aurora B kinase inhibitors in SCLC and perhaps other RB1 -/- cancers. SIGNIFICANCE: SCLC is rarely associated with actionable protooncogene mutations. We did a CRISPR/Cas9-based screen that showed that RB1 -/- SCLC are hyperdependent on AURKB , likely because both genes control mitotic fidelity, and confirmed that Aurora B kinase inhibitors are efficacious against RB1 -/- SCLC tumors in mice at nontoxic doses. See related commentary by Dick and Li, p. 169 . This article is highlighted in the In This Issue feature, p. 151 .
URI
https://repository.icr.ac.uk/handle/internal/3015
DOI
https://doi.org/10.1158/2159-8290.cd-18-0389
Collections
  • Breast Cancer Research
  • Molecular Pathology
Subject
Tumor Cells, Cultured
Animals
Humans
Mice
Mice, Nude
Lung Neoplasms
Ubiquitin-Protein Ligases
Antineoplastic Agents
Xenograft Model Antitumor Assays
Signal Transduction
Chromosome Segregation
Apoptosis
Cell Proliferation
Drug Resistance, Neoplasm
Mutation
Genes, Tumor Suppressor
Female
Small Cell Lung Carcinoma
Retinoblastoma Binding Proteins
Aurora Kinase B
CRISPR-Cas Systems
Research team
Gene Function
Language
eng
Date accepted
2018-10-05
License start date
2019-02
Citation
Cancer discovery, 2019, 9 (2), pp. 230 - 247

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.